University College London researchers lead £11M projects to investigate long-term effects of COVID-19 sciencebusiness.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencebusiness.net Daily Mail and Mail on Sunday newspapers.
Researchers develop a better solution to treat short bowel syndrome
Short Bowel Syndrome (SBS) is a medical disorder caused by a lack of a fully functional small intestine. Whether caused as a birth defect or because part of the small intestine was removed during surgery, SBS is a rare disorder, affecting approximately 13 000 people in the European Union. If left untreated, the condition can prevent the gut from performing its nutritional function.
Unfortunately, there is no cure for SBS, and current treatment options have low survival rates and can cause serious side-effects – especially for children. That is why researchers with the EU-funded INTENS project are committed to developing a better solution.
Institute of Child Health to add 80 beds About 450 children are treated at the hospital’s OPD every day
The Institute of Child Health will set up 80 more beds, taking the bed count of the Park Circus hospital to 300.
All 80 beds will be set up in an 11-storey building coming up on the campus, officials of the hospital said. The existing 220 beds will eventually be shifted to the new building.
Apurba Ghosh, paediatrician and director of the institute, said they were hoping to start functioning from the new building in two to three years. “We have 220 beds. We plan to add 80 more beds when the new building is ready,” he said.
E-Mail
The largest single cell study to date of the childhood cancer, neuroblastoma, has answered important questions about the genesis of the disease. The researchers from the Wellcome Sanger Institute, Great Ormond Street Hospital (GOSH) and the Princess Máxima Center for Pediatric Oncology, discovered that all neuroblastomas arise from a single type of embryonic cell called sympathoblasts.
The study, published today (5 February 2021) in
Science Advances, sought to understand why neuroblastomas range in severity, with some easy to treat and others having relatively low five-year survival rates. The fact that all neuroblastomas arise from sympathoblasts makes them an attractive drug target, because these cells exist only in the tumour after the child is born.
The Health of IVF Babies: What Do We Know? What Do We Need to Find Out?
Progress Educational Trust 23 February 2021 5.30pm-7pm (GMT)
A
today (
5.30pm-
The event will be chaired by
Professor Anja Bisgaard Pinborg (Chief Consultant at Rigshospitalet s Juliane Marie Centre in Copenhagen)
Dr Sebastiaan Mastenbroek (Senior Clinical Embryologist at Amsterdam UMC s Centre for Reproductive Medicine)
Dr Carrie Williams (Clinical Paediatrician and NIHR Research Fellow at University College London s Great Ormond Street Institute of Child Health)
Find out more about the speakers and chair here.
This event is produced by the